Lawmakers Can Highlight Tactics Designed to Block More Affordable Alternatives from the Market — Add to Momentum for Market-Based Solutions In Washington this week, Congress will hold a pair of hearings on the patent system, offering an opportunity for lawmakers to detail Big Pharma’s anti-competitive practices that drive higher prescription drug prices and add to
Big Pharma Trots Out Tired, Dishonest Arguments Designed to Evade Accountability, Keep Prices High As lawmakers in Congress continue to weigh market-based solutions to lower prescription drug…
Federal Trade Commission Workshop Highlights How Brand Name Drug Companies Game the System to Keep Prices High — Demonstrating the Urgency for Congress to Act This week…
FTC Workshop Can Highlight How Brand Name Drug Companies Employ Anti-Competitive Tactics to Game the System — Driven by Focus on Profits Over People This week…
Nearly Half of All New Brand Name Drugs Cost More Than $150,000 Per Year In case you missed it, a new academic study published in The Journal of the American Medical Association (JAMA) from…
Scoring Shows Solutions to Crack Down on Branded Drug Companies’ Anti-Competitive Tactics Would Save Consumers Billions and Bring More Affordable Alternatives to Market In case you missed it, on…
Brand Name Drug Companies Posted Massive Profit Growth and Invested Heavily in Share Buybacks and Dividends Two recent reports from Evaluate Vantage and Endpoints News detail the banner year Big…
Brand Name Drug Companies Four Times as Likely to Reformulate Blockbuster Products to Extend Market Exclusivity In case you missed it, a recent study published in JAMA Health Forum examines Big…
Brand Name Drug Companies Prevent Competition from More Affordable Alternatives by Gaming the Patent System and Deploying Tactics Like Product Hopping In case you missed it…
Part D Spending on 10 Most Popular Medications Over Five Years Averages Five Times What Drug Companies Claim to Invest in R&D In case you missed it…